

Henryk Barthel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12116928/publications.pdf>

Version: 2024-02-01

158
papers

9,727
citations

34105

52
h-index

40979

93
g-index

168
all docs

168
docs citations

168
times ranked

10145
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924. | 7.4 | 1,166 |
| 2 | Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939. | 7.4 | 501 |
| 3 | Cerebral amyloid- β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology, The, 2011, 10, 424-435. | 10.2 | 491 |
| 4 | Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimer's and Dementia, 2015, 11, 964-974. | 0.8 | 400 |
| 5 | In vivo staging of regional amyloid deposition. Neurology, 2017, 89, 2031-2038. | 1.1 | 321 |
| 6 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962. | 10.2 | 254 |
| 7 | Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurology, The, 2015, 14, 1037-1053. | 10.2 | 233 |
| 8 | 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research, 2003, 63, 3791-8. | 0.9 | 201 |
| 9 | Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles. Circulation Research, 2012, 110, 727-738. | 4.5 | 163 |
| 10 | SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. Journal of Nuclear Medicine, 2016, 57, 1316-1322. | 5.0 | 161 |
| 11 | Assessment of ¹⁸ F-FPI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408. | 9.0 | 145 |
| 12 | Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644. | 5.7 | 141 |
| 13 | Reduced α 4 β 2* α 7 Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease. Archives of General Psychiatry, 2009, 66, 866. | 12.3 | 140 |
| 14 | PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatric Radiology, 2013, 43, 860-875. | 2.0 | 136 |
| 15 | EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912. | 6.4 | 134 |
| 16 | Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84. | 11.0 | 133 |
| 17 | Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Research - Neuroimaging, 2005, 140, 63-72. | 1.8 | 132 |
| 18 | Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia. PLoS ONE, 2011, 6, e18111. | 2.5 | 129 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | The uptake of 3?-deoxy-3?-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 257-263. | 6.4 | 120 |
| 20 | Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015, 3, 13-26. | 2.1 | 120 |
| 21 | Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. <i>NeuroImage</i> , 2010, 49, 1490-1495. | 4.2 | 118 |
| 22 | ^{99m} Tc-Technetium-Ethyl-Cysteinate-Dimer Single-Photon Emission CT Can Predict Fatal Ischemic Brain Edema. <i>Stroke</i> , 1998, 29, 2556-2562. | 2.0 | 110 |
| 23 | Decreased cerebral $\alpha_4\beta_2$ nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 515-525. | 6.4 | 109 |
| 24 | Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. <i>Psychiatry Research - Neuroimaging</i> , 2013, 212, 230-236. | 1.8 | 107 |
| 25 | PET Quantification of ¹⁸ F-Florbetaben Binding to β_2 -Amyloid Deposits in Human Brains. <i>Journal of Nuclear Medicine</i> , 2013, 54, 723-731. | 5.0 | 101 |
| 26 | PET/MR in Dementia and Other Neurodegenerative Diseases. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 224-233. | 4.6 | 101 |
| 27 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228. | 9.0 | 97 |
| 28 | Individualized quantification of brain β_2 -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1702-1714. | 6.4 | 91 |
| 29 | Evaluation of early-phase [18 F]-florbetaben PET acquisition in clinical routine cases. <i>NeuroImage: Clinical</i> , 2017, 14, 77-86. | 2.7 | 91 |
| 30 | Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. <i>NeuroImage: Clinical</i> , 2017, 15, 325-332. | 2.7 | 89 |
| 31 | Permanent Middle Cerebral Artery Occlusion in Sheep: A Novel Large Animal Model of Focal Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1951-1964. | 4.3 | 88 |
| 32 | Redistribution of Nucleoside Transporters to the Cell Membrane Provides a Novel Approach for Imaging Thymidylate Synthase Inhibition by Positron Emission Tomography. <i>Cancer Research</i> , 2006, 66, 8558-8564. | 0.9 | 87 |
| 33 | Executive deficits are related to the inferior frontal junction in early dementia. <i>Brain</i> , 2012, 135, 201-215. | 7.6 | 87 |
| 34 | Serum neurofilament light chain in behavioral variant frontotemporal dementia. <i>Neurology</i> , 2018, 91, e1390-e1401. | 1.1 | 85 |
| 35 | EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651. | 6.4 | 82 |
| 36 | Clinical Use and Utility of Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1711-1717. | 5.0 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Impact of Training Method on the Robustness of the Visual Assessment of ¹⁸ F-Florbetaben PET Scans: Results from a Phase-3 Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 900-906. | 5.0 | 79 |
| 38 | In Vivo Evidence for Differential Association of Striatal Dopamine and Midbrain Serotonin Systems With Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 222-228. | 1.8 | 76 |
| 39 | Monoamine transporter availability in Parkinson's disease patients with or without depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 428-435. | 6.4 | 72 |
| 40 | Early [¹⁸ F]florbetaben and [¹¹ C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1700-1709. | 6.4 | 69 |
| 41 | The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 263S-272S. | 5.0 | 67 |
| 42 | Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. <i>Journal of Nuclear Medicine</i> , 2014, 55, 47S-55S. | 5.0 | 62 |
| 43 | Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. <i>Psychiatry Research - Neuroimaging</i> , 2009, 171, 120-128. | 1.8 | 61 |
| 44 | Dissociating behavioral disorders in early dementia—An FDG-PET study. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 235-244. | 1.8 | 61 |
| 45 | Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508. | 6.4 | 61 |
| 46 | Cognitive correlates of $\pm 4\beta 2$ nicotinic acetylcholine receptors in mild Alzheimer's dementia. <i>Brain</i> , 2018, 141, 1840-1854. | 7.6 | 60 |
| 47 | Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2004, 28, 547-563. | 6.1 | 59 |
| 48 | Dissociating Memory Networks in Early Alzheimer's Disease and Frontotemporal Lobar Degeneration - A Combined Study of Hypometabolism and Atrophy. <i>PLoS ONE</i> , 2013, 8, e55251. | 2.5 | 59 |
| 49 | Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸ F-Florbetaben $\beta 2$ -Amyloid PET Scans. <i>Journal of Nuclear Medicine</i> , 2016, 57, 198-203. | 5.0 | 58 |
| 50 | Potential Pediatric Applications of PET/MR. <i>Journal of Nuclear Medicine</i> , 2014, 55, 32S-39S. | 5.0 | 57 |
| 51 | Simultaneous PET/Mri in Stroke: A Case Series. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1421-1425. | 4.3 | 57 |
| 52 | Role of ¹⁸ F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 1009-1010. | 10.2 | 56 |
| 53 | Florbetaben to Trace Amyloid- $\beta 2$ in the Alzheimer Brain by Means of PET. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 117-121. | 2.6 | 52 |
| 54 | Cerebellar Amyloid- $\beta 2$ Plaques: How Frequent Are They, and Do They Influence ¹⁸ F-Florbetaben SUV Ratios?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1740-1745. | 5.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. <i>American Journal of Neuroradiology</i> , 2003, 24, 234-8. | 2.4 | 51 |
| 56 | Differentiation between Transient Ischemic Attack and Ischemic Stroke within the First Six Hours after Onset of Symptoms by Using ^{99m} Tc-ECD-SPECT. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 921-929. | 4.3 | 50 |
| 57 | Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1025-1032. | 6.4 | 50 |
| 58 | Comparison of ¹⁸ F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816. | 0.8 | 50 |
| 59 | Is correction for age necessary in neuroimaging studies of the central serotonin transporter?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 427-430. | 6.4 | 49 |
| 60 | First-in-human PET quantification study of cerebral $\alpha 4\beta 2$ nicotinic acetylcholine receptors using the novel specific radioligand (α)-[¹⁸ F]Flubatine. <i>NeuroImage</i> , 2015, 118, 199-208. | 4.2 | 49 |
| 61 | Cortical [¹⁸ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115. | 3.9 | 46 |
| 62 | Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. <i>Child's Nervous System</i> , 2014, 30, 1399-1403. | 1.1 | 45 |
| 63 | The need of standardization and of large clinical studies in an emerging indication of [¹⁸ F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357. | 6.4 | 44 |
| 64 | Reperfusion and Metabolic Recovery of Brain Tissue and Clinical Outcome After Ischemic Stroke and Thrombolytic Therapy. <i>Stroke</i> , 2000, 31, 1545-1551. | 2.0 | 39 |
| 65 | Quantitative Susceptibility Mapping of Amyloid- β Aggregates in Alzheimer's Disease with 7T MR. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 393-404. | 2.6 | 39 |
| 66 | Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8-12, 2013, Tübingen, Germany. <i>Molecular Imaging and Biology</i> , 2014, 16, 295-310. | 2.6 | 38 |
| 67 | Damaged Neocortical Perineuronal Nets Due to Experimental Focal Cerebral Ischemia in Mice, Rats and Sheep. <i>Frontiers in Integrative Neuroscience</i> , 2017, 11, 15. | 2.1 | 38 |
| 68 | Impaired Neurofilament Integrity and Neuronal Morphology in Different Models of Focal Cerebral Ischemia and Human Stroke Tissue. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 161. | 3.7 | 37 |
| 69 | Early-phase [¹⁸ F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922. | 6.4 | 36 |
| 70 | Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362. | 12.8 | 34 |
| 71 | Executive and behavioral deficits share common neural substrates in frontotemporal lobar degeneration - A pilot FDG-PET study. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 274-280. | 1.8 | 33 |
| 72 | Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120. | 6.4 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [¹²³ I]ÅŸ-CIT and high-resolution SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1656-1663. | 2.1 | 32 |
| 74 | Evaluation of software tools for automated identification of neuroanatomical structures in quantitative Î²-amyloid PET imaging to diagnose Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1077-1087. | 6.4 | 32 |
| 75 | Binding characteristics of [¹⁸ F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972. | 4.3 | 30 |
| 76 | Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2998-3007. | 6.4 | 29 |
| 77 | Serotonin Transporter Imaging with [¹²³ I]Î²-CIT SPECT before and after One Year of Citalopram Treatment of Obsessive-Compulsive Disorder. <i>Neuropsychobiology</i> , 2006, 53, 40-45. | 1.9 | 28 |
| 78 | Influence of scan duration on the accuracy of Î²-amyloid PET with florbetaben in patients with Alzheimerâ€™s disease and healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 238-244. | 6.4 | 28 |
| 79 | Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17. | 3.9 | 28 |
| 80 | In Vivo Correlation of Glucose Metabolism, Cell Density and Microcirculatory Parameters in Patients with Head and Neck Cancer: Initial Results Using Simultaneous PET/MRI. <i>PLoS ONE</i> , 2015, 10, e0134749. | 2.5 | 27 |
| 81 | The role of positron emission tomography imaging in understanding Alzheimerâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 395-406. | 2.8 | 27 |
| 82 | Validation of Noninvasive Tracer Kinetic Analysis of ¹⁸ F-Florbetaben PET Using a Dualâ€”Time-Window Acquisition Protocol. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1104-1110. | 5.0 | 27 |
| 83 | Age-specific cerebral perfusion in 4- to 15-year-old children: a high-resolution brain SPET study using ^{99m} Tc-ECD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1245-1252. | 6.4 | 26 |
| 84 | Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2013, 26, 159-171. | 2.0 | 26 |
| 85 | Early detection of amyloid load using ¹⁸ F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 67. | 6.2 | 26 |
| 86 | Feasibility and acceptance of simultaneous amyloid PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2236-2243. | 6.4 | 25 |
| 87 | Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET. <i>PLoS ONE</i> , 2013, 8, e55415. | 2.5 | 25 |
| 88 | Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. <i>Journal of Neuroimaging</i> , 2017, 27, 255-261. | 2.0 | 23 |
| 89 | International consensus on the use of tau PET imaging agent ¹⁸ F-flortaucipir in Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 895-904. | 6.4 | 23 |
| 90 | Feasibility of short imaging protocols for [¹⁸ F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885. | 6.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 878-888. | 2.1 | 21 |
| 92 | Prospective Value of Perfusion and X-Ray Attenuation Imaging With Single-Photon Emission and Transmission Computed Tomography in Acute Cerebral Ischemia. <i>Stroke</i> , 2001, 32, 1588-1597. | 2.0 | 21 |
| 93 | Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S329-S347. | 2.6 | 21 |
| 94 | Brain PET and functional MRI: why simultaneously using hybrid PET/MR systems?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 345-359. | 0.7 | 21 |
| 95 | PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 33S-44S. | 5.0 | 21 |
| 96 | Fully automated calculation of image-derived input function in simultaneous PET/MRI in a sheep model. <i>EJNMMI Physics</i> , 2016, 3, 2. | 2.7 | 20 |
| 97 | A new integrated dual time-point amyloid PET/MRI data analysis method. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2060-2072. | 6.4 | 20 |
| 98 | Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1105-1116. | 2.6 | 20 |
| 99 | First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1409-1410. | 5.0 | 20 |
| 100 | Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. <i>Journal of Neurology</i> , 2002, 249, 1082-1087. | 3.6 | 19 |
| 101 | Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration – A combined MRI & FDG-PET study. <i>NeuroImage: Clinical</i> , 2013, 2, 746-758. | 2.7 | 18 |
| 102 | Increased Immunosignals of Collagen IV and Fibronectin Indicate Ischemic Consequences for the Neurovascular Matrix Adhesion Zone in Various Animal Models and Human Stroke Tissue. <i>Frontiers in Physiology</i> , 2020, 11, 575598. | 2.8 | 18 |
| 103 | COVID-19 and the brain: impact on nuclear medicine in neurology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2487-2492. | 6.4 | 18 |
| 104 | Feasibility of in vivo 18F-florbetaben PET/MR imaging of human carotid amyloid- β . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1119-1128. | 6.4 | 17 |
| 105 | Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 425-432. | 2.6 | 16 |
| 106 | Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke. <i>Stroke</i> , 1999, 30, 787-792. | 2.0 | 15 |
| 107 | Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248. | 6.4 | 15 |
| 108 | Lesional and perilesional tissue characterization by automated image processing in a novel gyrencephalic animal model of peracute intracerebral hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2521-2535. | 4.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Academic-industry Collaborations in Translational Stroke Research. <i>Translational Stroke Research</i> , 2016, 7, 343-353. | 4.2 | 12 |
| 110 | Correlation of florbetaben PET imaging and the amyloid peptide A β 42 in cerebrospinal fluid. <i>Psychiatry Research - Neuroimaging</i> , 2017, 265, 98-101. | 1.8 | 11 |
| 111 | Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523. | 2.4 | 11 |
| 112 | Quantitative susceptibility mapping in β -Amyloid PET-stratified patients with dementia and healthy controls – A hybrid PET/MRI study. <i>European Journal of Radiology</i> , 2020, 131, 109243. | 2.6 | 10 |
| 113 | (+)-[18F]Flubatine as a novel β 2 nicotinic acetylcholine receptor PET ligand – results of the first-in-human brain imaging application in patients with β -amyloid PET-confirmed Alzheimer’s disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 731-746. | 6.4 | 10 |
| 114 | Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [¹⁸ F]PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2222-2234. | 3.5 | 10 |
| 115 | Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer’s Disease. <i>Journal of Alzheimer’s Disease</i> , 2017, 56, 441-446. | 2.6 | 9 |
| 116 | Citalopram Improves Obsessive-Compulsive Crossword Puzzling in Frontotemporal Dementia. <i>Case Reports in Neurology</i> , 2019, 11, 94-105. | 0.7 | 9 |
| 117 | Hypothesis and Theory: A Pathophysiological Concept of Stroke-Induced Acute Phase Response and Increased Intestinal Permeability Leading to Secondary Brain Damage. <i>Frontiers in Neuroscience</i> , 2020, 14, 272. | 2.8 | 9 |
| 118 | A realistic phantom of the human head for PET-MRI. <i>EJNMMI Physics</i> , 2020, 7, 52. | 2.7 | 9 |
| 119 | Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease. <i>Biomolecules</i> , 2022, 12, 458. | 4.0 | 9 |
| 120 | Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 89-96. | 6.4 | 8 |
| 121 | Exploiting the Full Potential of β -Amyloid and Tau PET Imaging for Drug Efficacy Testing. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1105-1106. | 5.0 | 8 |
| 122 | Alzheimer’s Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. <i>Journal of Alzheimer’s Disease</i> , 2015, 47, 539-543. | 2.6 | 7 |
| 123 | Combined PET/MRI. <i>Neurology</i> , 2016, 86, 1926-1927. | 1.1 | 7 |
| 124 | Reshaping the Amyloid Buildup Curve in Alzheimer Disease? Partial-Volume Effect Correction of Longitudinal Amyloid PET Data. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1820-1824. | 5.0 | 7 |
| 125 | Future Directions in Molecular Imaging of Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 68S-74S. | 5.0 | 7 |
| 126 | Small-animal imaging of tumour proliferation with PET. <i>Lancet Oncology</i> , The, 2004, 5, 100. | 10.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036. | 6.4 | 6 |
| 128 | Focal Cerebral Ischemia by Permanent Middle Cerebral Artery Occlusion in Sheep: Surgical Technique, Clinical Imaging, and Histopathological Results. <i>NeuroMethods</i> , 2016, , 195-225. | 0.3 | 6 |
| 129 | Changes in myocardial perfusion after catheter-based percutaneous laser revascularisation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1292-1299. | 2.1 | 5 |
| 130 | Finding our way through the labyrinth of dementia biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2320-2324. | 6.4 | 5 |
| 131 | Clinical Utility of 125 I-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 826-833. | 2.1 | 5 |
| 132 | Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report. <i>BMC Neurology</i> , 2015, 15, 152. | 1.8 | 4 |
| 133 | Early after Administration [11 C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 65-76. | 2.6 | 4 |
| 134 | Preclinical Aspects of Nicotinic Acetylcholine Receptor Imaging. , 2014, , 465-512. | | 4 |
| 135 | A comparison of advanced semi-quantitative amyloid PET analysis methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4097-4108. | 6.4 | 4 |
| 136 | Yes we can analyse amyloid images - Now What?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 822-824. | 6.4 | 3 |
| 137 | Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549. | 0.8 | 3 |
| 138 | PET/MRI Delivers Multimodal Brain Signature in Alzheimer's Disease with De Novo PSEN1 Mutation. <i>Current Alzheimer Research</i> , 2021, 18, 178-184. | 1.4 | 3 |
| 139 | ICP161: 18FPI2620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128. | 0.8 | 3 |
| 140 | Switching on Brain PET to Light Up Amyloid Pathology In Vivo (perspective on 18 F-ETQq000rgBT /Overlock 10 Tf | 5.0 | 3 |
| 141 | Potential of Rheopheresis for the Treatment of Acute Ischemic Stroke When Initiated Between 6 and 12 Hours. <i>Therapeutic Apheresis and Dialysis</i> , 2000, 4, 358-362. | 0.6 | 2 |
| 142 | Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039557. | 0.8 | 2 |
| 143 | Practical setting and potential applications of interventions guided by PET/MRI. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 43-50. | 0.7 | 2 |
| 144 | PET Imaging of Dementia. , 2012, , 244-250. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Differential Diagnosis Between Alzheimer's Disease-Related Depression and Pseudo-Dementia in Depression: A New Indication for Amyloid- β Imaging?. Journal of Alzheimer's Disease, 2022, , 1-7. | 2.6 | 2 |
| 146 | Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556. | 0.8 | 1 |
| 147 | ^{18}F -PI2620 tau-PET in corticobasal syndrome (ActiGliA cohort). Alzheimer's and Dementia, 2020, 16, e041469. | 0.8 | 1 |
| 148 | Proven validity and management impact of amyloid imaging in Alzheimer's disease "repetita juvant. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1787-1790. | 6.4 | 1 |
| 149 | Neurodegeneration Imaging. , 2018, , 99-106. | | 1 |
| 150 | Cerebral Blood Flow Measurement with Oxygen-15 Water Positron Emission Tomography. , 2014, , 103-124. | | 1 |
| 151 | Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 1 |
| 152 | ICA003: THE CAPTAINS STUDY: STANDARDIZING VISUAL INTERPRETATION STRATEGIES FOR AMYLOID PET TRACERS. Alzheimer's and Dementia, 2019, 15, P14. | 0.8 | 0 |
| 153 | Alzheimer's disease biomarker roadmap 2020: [^{18}F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550. | 0.8 | 0 |
| 154 | Quantitative thresholds for ^{18}F -florbetaben PET for the detection of low amyloid load. Alzheimer's and Dementia, 2020, 16, e042933. | 0.8 | 0 |
| 155 | Nicotinic acetylcholine receptors in patients with Parkinson's disease and Alzheimer's disease: Specific binding of 2-[^{18}F]F-A-85380 in the cerebral white matter as demonstrated by PET and comparison with diffusion tensor MRI (DTI). Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S584-S584. | 4.3 | 0 |
| 156 | PET Imaging of the ^{125}I Nicotinic Acetylcholine Receptors in Alzheimer's Disease. , 2021, , 345-365. | | 0 |
| 157 | 2018 SNMMI Highlights Lecture: Brain Nuclear and Molecular Imaging. Journal of Nuclear Medicine, 2018, 59, 11N-17N. | 5.0 | 0 |
| 158 | Feasibility of short imaging protocols for [^{18}F]PI2620 tau-PET in progressive supranuclear palsy. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |